Maria Sullivan, PA
Medical · Bridgeton, MONPI 1710541040
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by UCB, Inc. at 37.3% of the total.
Across 142 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$1K
- Novartis$357
- Johnson & Johnson$282
- AbbVie$249
- AstraZeneca$185
- Lilly USA, LLC$170
- plus $580 from 11 others
What the payments were for
- Food & beverage$2,80497%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 45 | $1,082 |
| Novartis | 26 | $357 |
| Johnson & Johnson(2 entities) | 11 | $282 |
| AbbVie | 12 | $249 |
| AstraZeneca(2 entities) | 11 | $185 |
| Lilly USA, LLC | 10 | $170 |
| Amgen | 8 | $157 |
| Sanofi | 4 | $140 |
| Pfizer | 4 | $76 |
| GSK | 3 | $58 |
| Tersera Therapeutics LLC | 1 | $33 |
| Genentech USA, Inc. | 2 | $29 |
| Octapharma USA, Inc. | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,904 in reported general payments places this provider in the 80th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 12 | $97,065 |
| MethotrexateMethotrexate Sodium | 81 | $2,396 |
| Hydroxychloroquine Sulfate | 52 | $1,898 |
| Leflunomide | 42 | $1,664 |
| Azathioprine | 29 | $1,294 |
| Sulfasalazine DrSulfasalazine | 35 | $1,169 |
| Gabapentin | 48 | $599 |
| Prednisone | 90 | $542 |
| Celecoxib | 18 | $513 |
| Diclofenac Sodium | 42 | $411 |
| Methylprednisolone | 35 | $329 |
| Cyclobenzaprine Hcl | 33 | $291 |
| Omeprazole | 11 | $155 |
| Meloxicam | 24 | $81 |
Paid to pharmacies, not to this prescriber.
Other medical in Bridgeton
- Melanie ChisamSpringfield$92K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
- Dustin BartlettSpringfield$21K
- Alexa Fider-WhyteSaint Louis$18K
- Megan Isaacson-SchmidSaint Louis$16K
- Erin YoffieSaint Louis$16K
- Corey WhitesidesColumbia$15K
- David WinchellSaint Peters$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.